Detalhe da pesquisa
1.
Opportunities to Improve Symptom Control with Somatostatin Congeners in GEP-NETs: A Review of Key Issues.
Oncologist
; 26(7): e1171-e1178, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-34097784
2.
Long-Term Safety Experience with Telotristat Ethyl Across Five Clinical Studies in Patients with Carcinoid Syndrome.
Oncologist
; 24(8): e662-e670, 2019 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-30651397
3.
Management of Diffuse Idiopathic Pulmonary Neuroendocrine Cell Hyperplasia: Review and a Single Center Experience.
Lung
; 196(5): 577-581, 2018 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-30167840
4.
Comprehensive genomic profiling in routine clinical practice leads to a low rate of benefit from genotype-directed therapy.
BMC Cancer
; 17(1): 602, 2017 Aug 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-28854908
5.
Defining the optimal timing of adjuvant therapy for resected pancreatic adenocarcinoma: A statewide cancer registry analysis.
J Surg Oncol
; 114(4): 451-5, 2016 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-27238300
6.
Impact of Previous Somatostatin Analogue Use on the Activity of Everolimus in Patients with Advanced Neuroendocrine Tumors: Analysis from the Phase III RADIANT-2 Trial.
Neuroendocrinology
; 102(1-2): 18-25, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-25824001
7.
Everolimus plus octreotide long-acting repeatable in patients with colorectal neuroendocrine tumors: a subgroup analysis of the phase III RADIANT-2 study.
Oncologist
; 18(1): 46-53, 2013.
Artigo
em Inglês
| MEDLINE | ID: mdl-23263288
8.
Time to Sustained Improvement in Bowel Movement Frequency with Telotristat Ethyl: Analyses of Phase III Studies in Carcinoid Syndrome.
J Gastrointest Cancer
; 52(1): 212-221, 2021 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-32146619
9.
A phase I/II study of rovalpituzumab tesirine in delta-like 3-expressing advanced solid tumors.
NPJ Precis Oncol
; 5(1): 74, 2021 Aug 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-34354225
10.
Primary Metastatic Small Intestinal Carcinoid Tumor Without Carcinoid Syndrome.
Oncology (Williston Park)
; 29(10): 755-6, 759, 2015 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-26470900
11.
Differential Diagnosis of Diarrhea in Patients With Neuroendocrine Tumors.
Pancreas
; 49(9): 1123-1130, 2020 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32991344
12.
In vitro chemoresistance testing in well-differentiated carcinoid tumors.
Ann Surg Oncol
; 16(3): 649-55, 2009 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-19130141
13.
Current Practices and Novel Techniques in the Diagnosis and Management of Neuroendocrine Tumors of Unknown Primary.
Pancreas
; 48(9): 1111-1118, 2019 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-31609931
14.
Multiple sclerosis outcomes after cancer immunotherapy.
Clin Transl Oncol
; 21(10): 1336-1342, 2019 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-30788836
15.
Global burden of neuroendocrine tumors and changing incidence in Kentucky.
Oncotarget
; 9(27): 19245-19254, 2018 Apr 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-29721198
16.
Telotristat ethyl in carcinoid syndrome: safety and efficacy in the TELECAST phase 3 trial.
Endocr Relat Cancer
; 25(3): 309-322, 2018 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-29330194
17.
Changes in Weight Associated With Telotristat Ethyl in the Treatment of Carcinoid Syndrome.
Clin Ther
; 40(6): 952-962.e2, 2018 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-29724499
18.
Prognostic Factors in Typical and Atypical Pulmonary Carcinoids.
Ochsner J
; 17(4): 335-340, 2017.
Artigo
em Inglês
| MEDLINE | ID: mdl-29230118
19.
mTOR Kinase Inhibition Effectively Decreases Progression of a Subset of Neuroendocrine Tumors that Progress on Rapalog Therapy and Delays Cardiac Impairment.
Mol Cancer Ther
; 16(11): 2432-2441, 2017 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-28864682
20.
Telotristat Ethyl, a Tryptophan Hydroxylase Inhibitor for the Treatment of Carcinoid Syndrome.
J Clin Oncol
; 35(1): 14-23, 2017 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-27918724